Cancel-Tassin G - Search Results

1

Functional characterization of 5p15.33 risk locus in uveal melanoma reveals rs452384 as a functional variant and NKX2.4 as an allele-specific interactor.

Derrien AC, Houy A, Ganier O, Dingli F, Ningarhari M, Mobuchon L, Espejo Díaz MI, Loew D, Cassoux N, Cussenot O, Cancel-Tassin G, Margueron R, Noirel J, Zucman-Rossi J, Rodrigues M, Stern MH. Derrien AC, et al. Am J Hum Genet. 2022 Dec 1;109(12):2196-2209. doi: 10.1016/j.ajhg.2022.11.004. Am J Hum Genet. 2022. PMID: 36459980 Free PMC article.

2

PCAP is the major known prostate cancer predisposing locus in families from south and west Europe.

Cancel-Tassin G, Latil A, Valéri A, Mangin P, Fournier G, Berthon P, Cussenot O. Cancel-Tassin G, et al. Eur J Hum Genet. 2001 Feb;9(2):135-42. doi: 10.1038/sj.ejhg.5200592. Eur J Hum Genet. 2001. PMID: 11313747

3

A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancer.

Maier C, Rösch K, Herkommer K, Bochum S, Cancel-Tassin G, Cussenot O, Häussler J, Assum G, Vogel W, Paiss T. Maier C, et al. Eur Urol. 2002 Sep;42(3):301-7. doi: 10.1016/s0302-2838(02)00280-4. Eur Urol. 2002. PMID: 12234517

4

[Genetic susceptibility to prostate cancer].

Cussenot O, Cancel-Tassin G. Cussenot O, et al. Med Sci (Paris). 2004 May;20(5):562-8. doi: 10.1051/medsci/2004205562. Med Sci (Paris). 2004. PMID: 15190476 Free article. Review. French.

5

Prostate cancer genetics.

Cancel-Tassin G, Cussenot O. Cancel-Tassin G, et al. Minerva Urol Nefrol. 2005 Dec;57(4):289-300. Minerva Urol Nefrol. 2005. PMID: 16247350 Review.

6

Genetic susceptibility to prostate cancer.

Cancel-Tassin G, Cussenot O. Cancel-Tassin G, et al. BJU Int. 2005 Dec;96(9):1380-5. doi: 10.1111/j.1464-410X.2005.05836.x. BJU Int. 2005. PMID: 16287462 Review. No abstract available.

7

Low penetrance genetic susceptibility to kidney cancer.

Thibault F, Cancel-Tassin G, Cussenot O. Thibault F, et al. BJU Int. 2006 Oct;98(4):735-8. doi: 10.1111/j.1464-410X.2006.06351.x. BJU Int. 2006. PMID: 16978268 Review. No abstract available.

8

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.

Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, Valeri A, Cancel-Tassin G. Cussenot O, et al. Eur Urol. 2007 Oct;52(4):1082-7. doi: 10.1016/j.eururo.2007.04.008. Epub 2007 Apr 13. Eur Urol. 2007. PMID: 17448593

9

Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms.

Larré S, Hamadeh H, Azzouzi AR, Vallancien G, Cochand-Priollet B, Cancel-Tassin G, Cussenot O. Larré S, et al. BJU Int. 2007 Sep;100(3):679-84. doi: 10.1111/j.1464-410X.2007.07079.x. BJU Int. 2007. PMID: 17669147

10

Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.

Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G. Cussenot O, et al. J Clin Oncol. 2007 Aug 20;25(24):3596-602. doi: 10.1200/JCO.2007.11.0908. J Clin Oncol. 2007. PMID: 17704407

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

171 results

Search Page

Filters